Your search history is turned on.
Date: May 7, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of...
CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John Crowley, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Fusion Pharmaceuticals Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact o...
CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John Valliant, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Fusion Pharmaceuticals Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact ...
30 Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations. You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and related notes appearing in Part I, Item I of this Quarterly Report on Form 10-Q and with our audited con...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to ____...
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates Presented interim data from TATCIST trial of FPI-2265 in mCRPC at the 2024 American Association for Cancer Research (AACR) Annual Meeting Signed definitive agreement to be acquired by AstraZeneca for total transaction value of up to $2.4 billion; transaction expected to close...
Date: May 2, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
printmgr file UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its...
Date: April 25, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
CERTIFICATE FUSION PHARMACEUTICALS INC. CERTIFICATE Reference is made to the special meeting (the Meeting) of shareholders of Fusion Pharmaceuticals Inc. (the Company) scheduled to be held on May 29, 2024. The undersigned, the duly appointed Chief Legal Officer of the Company, hereby certifies, for and on behalf of th...
Microsoft Word - Fuerte - Letter of Transmittal (4.22.24).docx - Updated LETTER OF TRANSMITTAL CERTIFICATED SHARES ONLY To accompany certificates representing common shares and common share purchase warrants of Fusion Pharmaceuticals Inc. The undersigned represents that I (we) have full authority to surrender without restriction the accompanying certificate(s)...
Scan QR for digital voting Copyright 2024 BetaNXT, Inc. or its affiliates. All Rights Reserved styleIPC The undersigned hereby appoints John Crowley, Maria Stahl and John Valliant, or _______________________________________ (print the name of the person the undersigned is appointing if this person is someone other than the management nominees listed), and each or either of them, as ...